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Taxanes constitute a family of naturally occurring diterpene
compounds including a potent antitumour drug, paclitaxel. Pacli-
taxel, originally isolated from the bark of the Pacific Yew tree (Taxus
brevifolia), has been shown highly effective in adjuvant and 
neo-adjuvant therapies for patients with breast and ovarian
cancers. More recently, its semisynthetic analogue, docetaxel, has
been introduced to breast cancer chemotherapy, which appears to
have expanded the number of diseases potentially sensitive to this
class of antitumour drugs. Both paclitaxel and docetaxel bind to
tubulin (Manfredi et al, 1982; Rao et al, 1992), inhibit micro-
tubule-disassembly (Schiff et al, 1979) and impair mitosis (Long
and Fairchild, 1994), thereby blocking progression through M
phase of the cell cycle and facilitating apoptosis (Jordan et al,
1996). In spite of the undoubted clinical success, some tumours
display innate or acquired resistance to these drugs. Three main
mechanisms of drug-resistance have been reported, (i) point muta-
tions of the tubulin gene (Bhalla et al, 1994), (ii) selection of
tubulin isoforms with low binding to taxanes (Kavallaris et al,
1997; Ranganathan et al, 1998) and (iii) expression of the multi-
drug-resistance (MDR) phenotype mediated by the P-glycoprotein
(P-gp) efflux pump encoded by the mdr1 (Horwitz et al, 1993;
Chevillard et al, 1996; Mechetner et al, 1998). The mechanism 
(iii) contributes to explain the innate resistance to paclitaxel and
docetaxel for tumours that often inherently express P-gp, such as
colon and kidney cancers (Naito and Tsuruo, 1998; Yu et al, 1998;
Gao et al, 1999). P-gp seems to be involved in the drug-resistance
of primary or metastatic tumours of the CNS, where molecules
very similar to P-gp (P-gp sister proteins) contribute to the genera-
tion of the brain–blood barrier and hamper the trafficking of the
bulky hydrophobic molecules such as paclitaxel and docetaxel
(Herrington et al, 1998). 
In order to discover and develop new taxanes active against
MDR-positive cells, a good number of taxanes derived from natur-
ally occurring 10-deacetylbaccatin III as well as 14-hydroxy-10-
deacetylbaccatin III have been designed, synthesized, and assayed
for their activities against P-gp positive cell lines (Ojima et al,
1996; Distefano et al, 1997; Ojima et al, 1998). Structure–activity
relationship study demonstrated that certain modifications at the
C10/C3′ positions of the taxane skeleton lead to the compounds
possessing high activity against MDR-positive cell lines (Ojima 
et al, 1996, 1997a, 1997b). In the present study, we selected three
of these novel and highly active taxanes to investigate their pattern
of antitumour activity in comparison with paclitaxel and doce-
taxel. This study clearly shows that newly developed taxanes
exhibit a spectrum of antitumour properties not fully overlapping
with and significantly better than those of paclitaxel and docetaxel,
justifying for these compounds to be defined as the second-
generation taxanes. 
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Summary Taxanes antitumour agents such as paclitaxel and docetaxel represent a successful family of chemotherapeutic drugs.
Unfortunately, acquired and innate resistance represents a clinical problem for these drugs. We investigated, on a panel of 7 human cancer cell
lines, the growth inhibition effect of 3 newly developed taxanes (SB-T-1213, SB-T-1250 and SB-T-101187) with modification at the C10 and C3′
positions of the taxane framework. These positions have been previously characterized as critical to make taxanes highly active against cells
overexpressing the efflux pump P-glycoprotein (P-gp). Paclitaxel and docetaxel were used as reference compounds. Results unambiguously
indicate the exceptional activity of the novel taxanes toward P-gp positive cells (up to >400 fold higher potency than that of paclitaxel). SB-T-
1213 and SB-T-1250 are also substantially more active than the reference compounds against P-gp negative cells. To better understand the
mechanisms underlying the enhanced activity of the newly developed taxanes, we performed cell cycle and apoptosis analysis. This study
demonstrates that the striking growth inhibition effect exhibited by the novel taxanes is ascribed to their increased ability in inducing apoptosis
and G2/M cell cycle block. SB-T-1213 and SB-T-1250 are also more active than reference compounds in inducing intracellular accumulation of
the beta-tubulin subunits. Finally, it is revealed that these novel taxanes have ability to inhibit the function of the P-gp efflux pump on the basis
of the Rhodamine 123 assay. These findings strongly suggest that SB-T-1213, SB-T-1250 and SB-T-101187 represent a new tool to overcome
innate or acquired P-gp mediated taxane-resistance. © 2000 Cancer Research Campaign http://www.bjcancer.com
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MATERIALS AND METHODS 
Drugs 
Docetaxel and paclitaxel were provided by Indena (Milan, Italy),
dissolved in DMSO (stock solution 10 mM) and used within 
7 days. Taxanes SB-T-101187, SB-T-1213 and SB-T-1250 were
synthesized using the procedures previously reported (Ojima et al,
1997a, 1997b, 1998) and used as DMSO solution in the same
manner as mentioned above. Chemical structures of all the drugs
used in this study are shown in Scheme 1. Control cells were
treated with the same amount of vehicle alone. The final DMSO
concentration never exceeded 0.1% (v/v), in either control or
treated samples. 
Cell culture 
A panel of seven human cancer cell lines was used. MCF-7wt, 
PC-3, DU145, NCIH23 and WiDr cells were purchased from the
American Type Culture Collection (Rockville, MD); the multi-
drug resistant (MDR) MCF-7 ADRr line, selected for adriamycin
resistance was kindly provided by Dr Kenneth H Cowan (National
Cancer Institute, NIH, Bethesda, MD). A2780 cells were
purchased from the European Collection of Cell Cultures
(ECACC, Salisbury, UK). Culture media were chosen according to
the suggestions of ATCC and ECACC. MCF-7 ADRr cells were
cultured in RPMI 1640 supplemented with 10 µ M of ADR. Cells,
propagated as monolayer culture in 75 cm2 tissue-culture flasks,
were trypsinized once or twice (depending on the cell type)
weekly and plated at a density of 8 × 104 cells ml–1. All cultures
were incubated at 37˚C under 5% CO2 95% air in a high humidity
atmosphere. MCF-7 ADRr cells exhibit the classical multidrug-
resistance (MDR) phenotype with mdr-1 mRNA and P-gp overex-
pression (De-Vincenzo et al, 1996). Experiments on P-gp function
were performed also in CEM VBLr cells (gift from M Cianfriglia,
Istituto Superiore di Sanità, Rome), an additional cell line
expressing the MDR phenotype. Cells were cultured in RPMI
1640 as indicated for MCF-7 ADRr cells. 
Growth experiments 
Cells were plated in 6-well flat bottom plates (Falcon, Lincoln
Park, NJ) at a concentration of 105 cells ml–1 in complete medium.
After 24 h, the medium was replaced with media containing the
test substances. Control cells were treated with vehicle alone.
Cells were then washed twice and cultures maintained up to 72 h
in complete medium (without removing drugs). At this time point
quadruplicate counts of triplicate cultures were performed. To
calculate the growth inhibition effect, three independent experi-
ments were performed for each drug/cell line. The IC50 values
were then calculated by fitting the concentration–effect curve data
obtained in the three experiments with the sigmoid-Emax model
using nonlinear regression, weighted by the reciprocal of the
square of the predicted effect (Motulsky and Ransnas, 1987). 
DNA analysis, tubulin expression and assessment of
apoptosis 
Cells were plated at a concentration of 105 cells ml–1 in the specific
medium supplemented as above. After 24 h, the medium was
replaced with fresh one containing the compounds to be tested or
vehicle alone. After various times of culture (from 24 h to 72 h)
cells were harvested and nuclei isolated and stained using a solu-
tion containing 0.1% Na+ citrate, 0.1% NP40, 4 mM EDTA and
50 µ g ml–1 propidium iodide (PI) as DNA dye (Ferlini et al, 1996).
Incubation of the cells with staining solution lasted a minimum of
12 h at 4˚C. Flow cytometric DNA analysis was performed by
acquiring a minimum of 2 × 104 nuclei with a Facscan flow
cytometer (Becton Dickinson, San Jose, CA). DNA fluorescence
was collected in linear mode and pulse signal processing was used
to set a doublet discrimination gate. Cell cycle analysis was
performed using Multicycle software package (Phoenix, San
Diego, CA). In other experiments, DNA analysis was performed in
whole cells in dual staining with microtubules. Briefly, cells were
fixed in cold methanol for 10 min at –20˚C. After one washing
pellets were re-suspended in cold acetone for 20 s. After two
washings, cells were labelled either with a FITC-conjugated
monoclonal antibody anti-α (diluted 1:50) or anti-β (diluted 1:25)
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Scheme 1tubulin (Sigma, St Louis, MO). After 1 h of incubation at 4˚C
samples were washed twice and maintained at 37˚C for 20 min in
PBS containing 50 U ml–1 of RNAse A (Sigma). Finally, PI at a
final concentration of 50 µ g ml–1 was added and incubation lasted
a minimum of 12 h at 4˚C. The expression of tubulin subunits (in
triplicate samples) was calculated in cells gated in G0/1 and G2/M
phases of the cell cycle. The mean channel of FITC fluorescence
was calculated for each condition. The mean of untreated cells
represented the 100%. Data are presented as the percent of the
control cells ± SD of the triplicates. 
The Apodirect kit (Pharmingen, San Diego) that includes all the
reagents to perform the d-UTP labelling of DNA strand breaks
measured Apoptosis. Kit was used following the manufacturer’s
suggestions. Apoptosis was determined in two independent
experiments in WiDr cells cultured for 3, 6, 12 and 24 h in the
presence of taxanes (at 1 and 2.5 nM, with exception of paclitaxel
that was used at 2.5 and 5 nM). 
Assessment of P-gp function
Rhodamine 123 (Rh123) fluorescent probe (Molecular Probes,
Eugene, OR) served to measure the functionality of the P-gp efflux
pump. Briefly, MCF-7 ADRr and CEM VBLr cells were loaded at
37˚C with 0.5 µ M of the dye in PBS supplemented by 0.2% of
BSA. After 15 min cells were transferred onto ice and washed two
times to remove Rh123 from the medium. After washing, 10 µ M
of the potential P-gp inhibitors was added and cells were kept at
37˚C over the period of 20 to 80 min. The positive control was
represented by quercetin (Sigma), a well known inhibitor of the 
P-gp function. An aliquot of cells was maintained on ice to prevent
dye efflux (control at 4˚C), whereas the maximal efflux was estab-
lished by adding the vehicle DMSO 0.1% and allowing the efflux
at 37˚C. Flow cytometry served to measure Rh123 fluorescence,
by acquiring 15000 cells with a Facscan flow cytometer equipped
with standard filters for green signal. Mean channel of the Rh123
fluorescence was calculated for each condition. The ratio of mean
channel between control at 37˚C and control at 4˚C was consid-
ered the control dye efflux. Similarly, the mean channel of Rh123
fluorescence of treated cells was divided over the control at 4˚C.
This ratio was divided over the control dye efflux to establish the
potency of P-gp inhibition. Results coming from two independent
experiments have been averaged and standard deviations are
reported in error bars. 
RESULTS 
Growth inhibition effect 
Growth inhibition effects of SB-T-1213, SB-T-1250 and SB-T-
101187 on cancer cells were assessed against a panel of seven
human cancer cell lines. Results are summarized in Table 1. When
considering results of the taxanes currently used in clinic,
docetaxel is always more active than paclitaxel (from 1.1 to 3.4
folds). SB-T-101187 shows a growth inhibition effect between
docetaxel and paclitaxel, with the exception of MCF-7 ADRr and
PC-3 cells. SB-T-1250 and SB-T-1213 showed a striking effect
against all cell lines, exhibiting substantially higher potencies than
that of paclitaxel (from 1.8 to 69-fold for SB-T-1250 and 3 to 412-
fold for SB-T-1213). 
DNA analysis and apoptosis 
In order to test if the gradient in antitumour activity of these novel
taxanes is parallel to the blocking activity, we have performed
DNA analysis in WiDr cells. After 24 hours of culture, the taxane-
treatment of WiDr cells blocks the cell cycle at the G2/M phase
(Figure 1). The increase in the number of blocked cells appears
dose dependent for all taxanes and the higher extent of cell cycle
block is observed at 5 nM for all drugs. After 72 hours of culture,
a large part of blocked cells exits from the M phase. This exit is
followed by an increase of DNA fragmentation, suggesting that
the majority of blocked cells undergo apoptosis, as previously
demonstrated for paclitaxel and docetaxel in other cell lines.
However, the number of cells showing hypo-diploid DNA content
does not correlate with the block. The largest amount of frag-
mented DNA is observed at concentrations lower than 5 nM. For
paclitaxel, docetaxel and SB-T-101187 the peak of DNA fragmen-
tation occurs at 2.5 nM, while for SB-T-1213 and SB-T-1250 the
peak appears at 1 nM. 
To ascertain the actual amount of cells undergoing apoptosis,
we chose a method to score apoptosis that allows the identification
of the cell cycle phase from which the cell death process stems.
The technique (tunel assay) is based on the labelling of DNA-
strand breaks (occurring in cells undergoing early apoptosis) by
the terminal deoxynucleotide transferase enzyme that incorporates
a marked nucleotide (BrDu-FITC) in the DNA chain (Darzynkie-
wicz et al, 1997). The assay was performed after 3, 6, 12 and 24
hours of the WiDr cell culture in the presence of taxanes. Figure 2
shows a representative analysis of the most active agent SB-T-
1213. The exposure of DNA-strand breaks starts from 3 and
progressively increases up to 12 hours. After an additional 12
hours of culture, a smaller number of cells with exposed DNA-
strand breaks becomes detectable. Concomitantly, a subset of cells
with a DNA content higher than 4C (indicated by double arrows in
Figure 2E) comes into the view, along with the increase in the
number of hypo-diploid cells (indicated by arrows in Figure 2E).
Interestingly, these cells were completely devoid of DNA-strand
breaks in this system. By this method, we were able to score the
actual amount of apoptosis (length of bars in Figure 3). The ability
of the taxanes in inducing apoptosis followed the same order of
potency observed for the cell cycle-block and the growth inhibi-
tion effect. Moreover, we observed that the maximal occurrence of
DNA-strand breaks started from the G2/M phase of the cell cycle.
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Table 1 IC50 values (expressed in nM) against a panel of human cancer cell lines 
Drug A2780 MCF-7 wt MCF-7 ADRr WiDr PC-3 DU-145 NCI-H23 
Paclitaxel 5.4 5.8 3300 3.8 3.4 1.5 4.1 
Docetaxel 4.95 3.6 970 2.3 1.8 0.8 3 
SB-T-101187 5.16 5.6 108 3 3.8 0.7 2.9 
SB-T-1250 3.03 2.3 48 0.5 0.7 0.6 1.6 
SB-T-1213 1.77 0.9 8 0.4 0.3 0.3 0.7 All these findings indicate that apoptosis is triggered, in a dose-
dependent manner, in cells blocked at G2/M phase of the cell cycle.
However, the DNA release, resulting in the generation of hypo-
diploid cells, is hampered when concentrations higher than 1 nM
of SB-T-1213 or SB-T-1250 and 2.5 nM of the other taxanes are
used. This phenomenon can be likely ascribed to the stiffening of
the microtubule network. 
Analysis of tubulin expression 
Flow cytometry was used to evaluate the expression of α - and 
β -tubulin isotypes in WiDr cells treated with 1 and 2.5 nM of
taxanes for 24 hours. Analysis was performed in dual staining with
PI as DNA dye. This method allowed us to assess tubulin expres-
sion in cells gated in the G0/1 and G2/M phase. The drug-treatment
does not affect α -tubulin significantly at both concentrations,
whereas results for β -tubulin isotype are summarized in Figure 4.
β -tubulin is upregulated by SB-T-1213 and SB-T-1250 at 1 nM
without differences between cells gated at G0/1 and G2/M. Increase
in taxane concentration induces the augmentation of β -tubulin for
the remaining drugs. There is no significant difference between
cells gated in G0/1 and G2/M in this case as well. A tall conditions
examined, the increase never exceeds 3-fold of the value of
control cells, indicating the saturation in the tubulin-binding of
taxanes. 
Effect of newly developed taxanes on P-gp function 
The functional activity of the P-gp efflux pump was firstly investi-
gated by incubating MCF-7 ADRr cells (loaded with the cationic
probe Rh123) in the presence of 10 µ M of SB-T-1213, SB-T-1250
and SB-T-101187. Three types of controls were used, (i) cells kept
on ice to prevent the active efflux of Rh123 (maximal loading); (ii)
cells maintained at 37˚C to allow the dye efflux (maximal efflux);
(iii) cells treated by 10 µ M of quercetin, a well known inhibitor of
the P-gp function (Shapiro and Ling, 1997). Cells treated by
Cytotoxic and P-gp reversal taxanes 1765
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Figure 1 Line charts showing results of DNA analysis in WiDr cells cultured for 24 (A–B) and 72 (C–D) hours in the presence of taxanes (concentration range
0.5–5 nM). In the graphs A and C the percent of cells blocked in G2/M phase of the cell cycle is shown. In the graphs B and D, the amount of events in the
hypo-diploid region is depicted. The following symbols are used: open circle (paclitaxel), black circle (docetaxel), open triangle (SB-T-101187), black triangle
(SB-T-1213), and open square (SB-T-1250). SD bars have been omitted to add clarity to the graphs. *P < 0.05 vs. the control quercetin and taxanes were maintained at 37˚C to allow the
maximal dye efflux. Results are summarized in Figure 5. SB-T-
1213 and SB-T-101187 are the most potent agents among the
examined drugs. Moreover, it should be noted that the kinetic of P-
gp inhibition by SB-T-1213 and SB-T-101187 appears different
from that of quercetin, i.e., the activity of SB-T-1213 and SB-T-
101187 decreases as the time goes by whereas P-gp inhibition of
quercetin is stable during the time course. SB-T-1250 also shows
substantially weaker inhibitory activity of P-gp function as
compared to those of SB-T-1213 and SB-T-101187. As antici-
pated, docetaxel is completely inactive for the modulation of 
P-gp function. In order to confirm these findings, we repeated the
same experiments in an additional P-gp positive cell line (CEM
VBLr), confirming the results in terms of P-gp inhibition (data not
shown). 
DISCUSSION 
The introduction of paclitaxel and docetaxel in cancer
chemotherapy has significantly improved the clinical course of
diseases such as ovarian and breast cancers (Verweij et al, 1994).
However, some tumour histotypes such as those in colon, kidney
and CNS appear to be poorly responsive to this class of drugs.
Unfortunately, the same phenomena occur in the cancer patients
relapsing after taxane treatment. New hopes to overcome these
problems may stem from our present study. We examined the
profile of the antitumour properties of 3 newly developed
taxanes SB-T-1213, SB-T-1250 and SB-T-101187. It is note-
worthy that SB-T-1213 and SB-T-1250 have exhibited strikingly
high potency in all the biological effects examined. These two
novel taxanes can block cell cycle, hamper β -tubulin depolymer-
ization and induce apoptosis at a concentration 2.5 times lower
than that required by the other taxanes, including paclitaxel and
docetaxel. Moreover, we have discovered the mechanism under-
lying their excellent activity against P-gp positive cells. These
novel taxanes act as cytotoxic agents and at the same time inhibit
the function of the P-gp efflux pump. This property is absolutely
unique in the field of the antitumour agents and could produce
several potential advantages: (i) overcoming drug resistance
mediated by the expression of the MDR phenotype; (ii)
possessing strong activity in those cancers that inherently
express low levels of the P-gp pump (such as colon and kidney
cancers); (iii) possible synergistic combinations with other anti-
tumour agents such as anthracyclines that are substrates for the
P-gp protein. Previous attempts to modulate P-gp function using
a two-drug approach (such as r-verapamil, tamoxifen) failed to
produce positive clinical results, and these findings contributed
to the current thinking that P-gp is not a relevant cause of drug-
resistance in solid tumours (Kaye, 1998). However, it is possible
that interpretation of the results from these trials is complicated
by pharmacokinetic interactions between the target cytotoxic
drug and the P-gp-reverting agent and the use of a single drug
with intrinsic ability of P-gp inhibitor will contribute to under-
stand which is the actual relevance of P-gp in the development of
drug-resistance. It is also anticipated that these novel taxanes
may well have more diverse pharmacokinetic profile as
compared to those of paclitaxel and docetaxel, because P-gp
belongs to a superfamily of highly-conserved proteins, named
ABC, ATP Binding Cassette, that are responsible for the vast
majority of trafficking of the bulky hydrophobic molecules
(including intestinal absorption and crossing of the haemato-
encephalic barrier) (Torok et al, 1999). On the other hand, the
interaction with the P-gp function could increase toxicity
towardhaematopoietic progenitors and produce adverse effects in
the most immature haematopoietic cells. Indeed, haematopoietic
progenitors express on their membranes P-gp in a manner to
protect this precious cell source from noxious xenobiotics
(Smeets et al, 1997). The protein is highly expressed at the level
of the most immature CD34+ cells, whereas during the course of
differentiation the pump is gradually lost (Uchida et al, 1996).
Thus, the assessment of toxicity in the haematopoietic compart-
ment is mandatory prior to hypothesizing a possible clinical use.
Nevertheless, the remarkable antitumour properties and the
ability to inhibit P-gp function described here warrant further
investigations to identify the mechanism(s) of the P-gp inhibition
by these novel taxanes as well as the pharmacokinetic properties
in animal models. These studies will further advance the 
development of a ‘second generation’ of taxanes, hoping to
obtain drugs with an enhanced spectrum of activity and
improved pharmacological properties. 
1766 C Ferlini et al
British Journal of Cancer (2000) 83(12), 1762–1768 © 2000 Cancer Research Campaign
1
0
2
3
0
1023 0
A
2C 4C
1
0
2
3
0
1023 0
B
2C 4C
1
0
2
3
0
1023 0
C
2C 4C
1
0
2
3
0
1023 0
D
2C 4C
1
0
2
3
0
1023 0
E
2C 4C
DNA content
d
-
U
T
P
 
F
I
T
C
 
f
l
u
o
r
e
s
c
e
n
c
e
Figure 2 Representative dot density plots of the DNA content vs. d-UTP
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Figure 4 Box plots show the results of tubulin analysis after 24 hours of
culture in the presence of 1 nM (A, circle) and 2.5 nM (B, square) of taxanes.
Samples were prepared in triplicate for each condition. Symbols and bars are
mean and standard deviations of the triplicates, respectively. Results in y-axis
are expressed as percentage of the control (DMSO 0.1%). Open and closed
symbols are referred to as cells gated at the G0/1 and G2/M phase of the cell
cycle, respectively. Interestingly, when the alteration of the beta tubulin
expression occurs, the over expression also takes place at the G0/1 phase 
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Figure 5 Bar chart of P-gp inhibition of the panel of taxanes. MCF-7 
ADRr cells were loaded with Rh123 (0.5 µ M). After 15 min., cells were
transferred onto ice and washed twice in cold PBS/BSA 0.2%. On to ice was
added 10 µ M of all the tested drugs or the vehicle DMSO 0.1%. Cells were
then kept at 37˚C to allow the maximal dye efflux.An aliquot of cells was
maintained on ice to have the maximal dye uptake. At each time point (from
20 to 80 min), Rh123 fluorescence was assessed by flow cytometry. 
The ratio between control at 37˚C and control at 4˚C served to calculate the
control dye efflux. The same procedure was employed for each drug. This
ratio was divided by the amount of the control dye efflux. A value higher than
1 means that drug acts as P-gp inhibitor. Results obtained from the mean of
two independent experiments are shown. Bars represent the standard
deviations 1768 C Ferlini et al
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